SAPPORO CLINICAL LABORATORY INC., First Half Ordinary Profit Revised Upward to an Unexpected 16% Increase

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Nov 1, 2024 3:30 pm JST Revision

9776 SAPPORO CLINICAL LABORATORY INC. 【J-GAAP】

Guidance Update Report

SAPPORO CLINICAL LABORATORY INC. <9776> [TSE-S] announced a performance revision after the market closed on November 1st (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) has been revised upward by 51.8%, from the previous forecast of 226 million yen to 343 million yen (compared to 296 million yen in the same period of the previous year), turning to a 15.9% increase in the consolidated ordinary profit outlook.

Furthermore, the full-year ordinary profit forecast remains unchanged from the estimate of 493 million yen(compared to 514 million yen in the previous period).

Kabutan News

Guidance Update

First Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024 Prev	9,801	221	226	141	45.2	0	May 13, 2024	J-GAAP
Apr - Sep, 2024 New	9,996	337	343	222	71.2	0	Nov 1, 2024	J-GAAP
Revision Rate	+2.0%	+52.5%	+51.8%	+57.4%	+57.4%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2023	9,862	291	296	226	67.9	0	Nov 10, 2023	J-GAAP
Apr - Sep, 2024 Guidance	9,996	337	343	222	71.2	0	Nov 1, 2024	J-GAAP
YoY	+1.4%	+15.8%	+15.9%	-1.8%	+4.7%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	20,127	1,008	1,159	568	170.5	23	May 12, 2023	J-GAAP
Mar, 2024	19,682	534	514	380	114.1	23	May 13, 2024	J-GAAP
Mar, 2025 Guidance	19,799	500	493	320	102.6	23	May 13, 2024	J-GAAP
YoY	+0.6%	-6.4%	-4.1%	-15.8%	-10.1%